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Introduction
Antimicrobial resistance (AMR) poses a serious threat to modern medicine and may render
common infections untreatable. The discovery of new antibiotics has come to a relative stand-
still during the last decade [1], and developing novel approaches to tackle the spread of AMR
genes will require significant efforts in the coming years [2]. In 2014, several groups indepen-
dently demonstrated how CRISPR-Cas (clustered regularly interspaced short palindromic
repeats-CRISPR–associated), a bacterial immune system now widely used for genome editing,
can selectively remove AMR genes from bacterial populations. Here, we discuss the current
state of the field of CRISPR-Cas antimicrobials, the challenges ahead, and how they may be
overcome.
Using CRISPR-Cas to target AMR in bacteria
CRISPR-Cas is an immune system that protects bacteria and archaea against invading nucleic
acids. Short sequences (‘spacers’) derived from foreign DNA or RNA elements, such as bacteri-
ophages and plasmids, are inserted in CRISPR loci on the bacterial genome and later used by
the Cas protein machinery to recognise and destroy invading nucleic acids carrying the same
sequence. CRISPR-Cas systems are classified into two classes and six types, in which class 1
(types I, III, and IV) have a more complex architecture, with multiple Cas proteins participat-
ing in foreign DNA recognition and cleavage processes, whereas class 2 systems (types II, V,
and VI) have simpler architecture, with recognition and cleavage carried out by a single multi-
domain enzyme. The latter class encompasses the type II CRISPR-Cas9 system, whose target-
ing specificity, versatility, and simplicity has led to many revolutionary applications in genome
editing and ecological engineering. While most of these applications have been thoroughly
reviewed [3], one that has received comparatively little attention is using CRISPR-Cas to eradi-
cate AMR genes from bacterial populations and communities.
It was initially postulated several years ago that a synthetic CRISPR-Cas system could be
utilised as an antimicrobial to kill specific bacterial genotypes [4]. More recent studies have
confirmed the potential for CRISPR-Cas to precisely remove bacterial strains that carry genes,
including those determining drug resistance, from populations and to re-sensitise bacteria to
antibiotics by selectively removing AMR-encoding plasmids.
Highlighting the specificity of CRISPR-Cas antimicrobials, individual bacterial strains were
selectively removed from a mixed population of Escherichia coli genotypes by transforming the
population with a plasmid encoding CRISPR-Cas programmed to target a sequence unique to
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each genotype [5]. Two studies demonstrated that CRISPR-Cas9 can be delivered using phage-
mids (plasmids packaged in phage capsids) to selectively kill the clinically relevant bacterial
pathogens E. coli [6] and Staphylococcus aureus [7]. One of these studies used phagemid trans-
duction to deliver CRISPR-Cas9 constructs programmed to target AMR genes harboured on
plasmids, which effectively removed these plasmids from bacteria. In addition, delivery of
CRISPR-Cas9 by conjugative plasmids was used to kill bacteria carrying AMR genes in the
chromosome [6]. The other study demonstrated sequence-specific killing of bacteria harbour-
ing virulence genes using phagemid-mediated delivery of CRISPR-Cas9 and also showed that
this approach was able to remove plasmids carrying AMR genes, thus effectively re-sensitising
bacteria to antibiotics [7]. Both studies also showed that the CRISPR-Cas9 phagemids are able
to kill specific bacteria in vivo, either in Galleria mellonella larvae exposed to enterohaemor-
rhagic E. coli [6] or on the skin of mice colonised with S. aureus [7].
While these studies showed that bacteria can be re-sensitised to antibiotic treatment using
CRISPR-Cas, a clear problem was that these bacteria have no selective benefit over resistant
ones, allowing residual resistant bacteria to be maintained in the population. In an attempt to
increase the selective advantage of re-sensitised bacteria, a technology using temperate and
lytic phage to re-sensitise bacteria to β-lactam antibiotics was developed [8]. In this case,
CRISPR-Cas programmed to target AMR genes was delivered by a temperate phage. This
CRISPR-Cas construct also conferred resistance to lytic phage, providing a subsequent selec-
tive advantage to re-sensitised bacteria that were challenged with this type of phage [8]. A fur-
ther study implemented CRISPR-Cas9 for broad-spectrum targeting of common β-lactamase
gene classes in E. coli by identifying a shared target sequence in>200 mutational variants of
this gene [9], thus circumventing the problem of high sequence diversity among β-lactamase
genes [10].
Challenges ahead
Complex microbial communities
Although CRISPR-Cas clearly has massive potential for the sequence-specific killing or re-sen-
sitisation of AMR-carrying bacteria, at present, the use of CRISPR-Cas to remove AMR genes
has only been assessed in near-clonal bacterial populations. Using such an approach in real-
world environments, where bacteria are typically embedded in a microbial community [11],
will be far more challenging. Natural microbial communities found within human, animal,
and environmental microbiomes contain billions of cells per gram of matrix, consisting of
thousands of species. Even within single species or strains, clonal lineages may possess differ-
ent plasmids and other mobile genetic elements (MGEs) bearing diverse resistance genes.
Quantitative PCR and next-generation sequencing allow quantitation and characterisation of
bacterial hosts, MGEs, and resistance genes. However, determining resistance-gene carriage
by specific bacterial hosts within complex communities requires more time-consuming
approaches such as fluorescence-activated cell sorting of genetically tagged bacteria and
MGEs prior to downstream analyses. Alternatively, recently developed methodologies such as
epicPCR [12] and Meta3C [13] may be used to determine mobile gene carriage by specific host
bacteria without the need for cultivation.
Another challenge associated with microbial communities is the difficulty in predicting
community-wide responses to perturbations. Introducing CRISPR-Cas–based antimicrobials
may have unwanted knock-on effects: If a strain is removed from a population, or its growth
or metabolism is affected by removal of a particular plasmid, this may allow other, potentially
more clinically problematic species to outgrow it. For example, it is well established that stress-
induced alterations to microbial community composition and metabolite levels are associated
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with an increase in susceptibility to Clostridium difficile infection in the gut [14], and shifts in
the species structure of the microbiome are linked with human disease states including diabe-
tes and periodontitis [15]. The consequences of AMR removal by CRISPR-Cas in various
microbial communities are to date unknown, and these risks must be assessed.
CRISPR-Cas delivery vehicles and architecture
AMR genes are present in and spread amongst a wide range of bacterial species; they are fre-
quently encoded on plasmids, which spread through horizontal gene transfer across diverse
bacterial species [11]. Whilst phages can be powerful vectors for CRISPR-Cas delivery, the
host ranges of most phage species are narrow, presenting an obvious barrier to targeting multi-
ple bacterial species. Moreover, using this approach in spatially structured and complex micro-
bial communities will provide an additional challenge, as the encounter rates between phages
and their host bacteria will be reduced. Approaches to circumvent these challenges have been
suggested, such as engineering phages to expand their host range [16, 17]; however, this tech-
nology remains at a preliminary stage. Another potential delivery vector is conjugative plas-
mids, which are transferred between bacteria, but restrictions such as narrow host range,
barriers to plasmid uptake and establishment [11], and conjugation efficiency remain [6].
Finally, it is vital to consider the efficacy of various CRISPR-Cas systems in specific hosts, as
cytotoxicity has hampered the effective use of Cas9 in some species. For example, in Synecho-
coccus elongatus, a cyanobacterium, Cas9 is lethal when expressed constitutively [18], and
attempts to use Cas9 in Corynebacterium glutamicum were also unsuccessful because of the
toxicity of this nuclease [19]. However, in both of these cases, the alternative class 2 nuclease
Cas12a was effectively used.
Resistance evolution against CRISPR-Cas
Another issue is the evolution of resistance to CRISPR-Cas. In the context of CRISPR–phage
interactions, this is known to occur readily through the acquisition of point mutations in the
sequence targeted by CRISPR-Cas [20]. In principle, this could also happen in AMR genes
that are targeted for removal, particularly if these AMR genes are under positive selection (e.g.,
when antibiotics to which the AMR gene confers resistance are used). Alternatively, resistance
could evolve by inactivation of CRISPR-Cas loci through mutations or deletions in cas genes
essential for target cleavage or by deleting targeting spacers [4, 21, 22]. Data from studies on
CRISPR-Cas9–based antimicrobials suggest that mutations of target sequences are far less
likely to occur than the delivery of defective CRISPR systems [6, 7]. Apart from the evolution
of resistance through mutation, resistance can also evolve by selection for anti-CRISPR (acr)
genes, which encode small proteins that bind to and inactivate critical components of the
CRISPR-Cas immune system. At present, over 20 unique families of acr genes that target both
type I and II CRISPR-Cas systems have been identified [23, 24]. Many of the Acr protein fami-
lies targeting type I CRISPR-Cas systems have been identified in phages infecting Pseudomonas
aeruginosa as well as other species within the proteobacteria. Although most of these Acr pro-
teins appear to be specifically targeting one CRISPR-Cas subtype, one Acr has been identified
that targets both the type I-E and I-F CRISPR-Cas subtypes [25], suggesting that more broad-
range Acrs may exist. More recently, Acr proteins have been identified that target type II sys-
tems—which encompass the CRISPR-Cas9 systems used for gene editing [26]—one of which
is notably broad in its target range [27]. The massive sequence diversity and high specificity of
Acrs suggests that they are likely ubiquitous and possibly carried by MGEs such as phages and
plasmids to circumvent targeting by CRISPR-Cas. Both the evolutionary consequences of
CRISPR-Cas targeting of AMR genes and its impact on population dynamics require further
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study, especially using more realistic microbial communities to understand the ecological and
evolutionary risks of this approach.
Legislation and responsible governance of CRISPR-Cas–based
antimicrobials
Upon development of a CRISPR-Cas system to remove AMR genes from environmental bacte-
rial communities, the use of this technology would face a number of legislative and social
issues. Exercising caution and fully assessing the risks when releasing or using gene-editing
systems in the environment is essential. It has been suggested that there is a need for updated
nongovernmental guidelines on the release of CRISPR-Cas and other gene-editing constructs
that can be used to modify the genetic material of environmental populations, as well as a need
for national and international bodies to develop guidance and legislation around the use of
this new technology [28]. In addition to technical guidelines, community engagement is
important, both to receive advice on best practices and gauge public and stakeholder support
for the use of such technologies [29].
Overcoming these challenges
Although the obstacles to using CRISPR-Cas as a tool to tackle AMR are numerous, there are
potential solutions to circumvent some of these challenges (summarised in Fig 1). The most
pressing issue facing the use of CRISPR-Cas9–mediated removal of AMR is finding an appro-
priate delivery vector [6, 17] that is tailored for its particular purpose. For example, phage-
mediated delivery may be the method of choice during an acute infection. However, even
strains of the same bacterial species commonly vary in phage susceptibility, and alternative
delivery vehicles may be desirable. Whilst their spread in microbial communities is slow, the
wider host range of some conjugative plasmids would make them suitable candidates for use
with a probiotic to protect against invasion by AMR-carrying bacteria or to remove micro-
biome-associated reservoirs of AMR. Although fitness costs associated with conjugative plas-
mids can limit their spread, these can be quickly offset by mutations in both the bacterial
host and the plasmid [30–32], which could benefit the spread of a CRISPR-Cas–encoding plas-
mid in the community. The improvement of these tailored delivery systems would be a step
towards tackling the challenge of the complexity of microbial communities, if a suitable broad
host range vector could be identified or engineered.
Unpredictable ecological responses of a microbial community to the spread of CRISPR-Cas
delivery vectors will be a major hurdle for the feasibility of using CRISPR-Cas antimicrobials
in the real world. The ecological consequences of using CRISPR-Cas antimicrobials in a com-
munity context therefore need to be carefully studied by monitoring the effect of the removal
of AMR genes on the frequency of other bacterial species and their associated plasmids.
Especially in the context of long-term applications, the evolution of resistance appears
almost inevitable. However, resistance through mutation of target sequences can potentially
be avoided by multiplexing, which involves CRISPR-Cas targeting of multiple sequences
simultaneously to reduce the likelihood of resistance [33, 34]. The ease with which CRISPR-
Cas (and CRISPR-Cas9 in particular) can be reprogrammed means this method can be
adapted as needed and remains feasible. Selection for acr genes may be mitigated through
using multiple CRISPR-Cas variants simultaneously, which would require different Acrs to
escape targeting or engineering Acr-insensitive CRISPR-Cas variants. An approach using
alternative nucleases to Cas9, such as Cas12a, may also circumvent any issues with the toxicity
and efficacy of the system in various bacterial hosts.
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Fig 1. Challenges associated with CRISPR-Cas antimicrobials and potential routes to overcome them. A summary of the obstacles
associated with using CRISPR-Cas–based antimicrobials in complex environmental populations of bacteria is shown. These include ensuring
effective delivery of constructs (top left), routes of resistance evolution to these novel antimicrobials (top right), the species diversity and spatial
complexity of bacterial communities (bottom left), and uncertainty in usage guidelines and stakeholder support (bottom right). AMR,
antimicrobial resistance; CRISPR-Cas, clustered regularly interspaced short palindromic repeats-CRISPR–associated.
https://doi.org/10.1371/journal.ppat.1006990.g001
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006990 June 14, 2018 5 / 8
Future prospects
Many hurdles remain that need to be overcome before CRISPR-Cas can be used to target
AMR in natural microbial communities. Identification of a suitable delivery method will be
key to fully exploit the potential of this technology for limiting the environmental and clinical
spread of AMR by MGEs. Simple reprogramming of CRISPR-Cas constructs to target particu-
lar genes of interest will greatly enhance the efficiency with which this can be achieved. Such
an advance may have implications for tackling reservoirs of resistance and potentially help to
retain or regain the antimicrobial activity of antibiotics. Future research is required to study
and optimise the spread of CRISPR-Cas in more realistic microbial communities and to
understand the risks associated with this technology. In addition, the social and legislative
challenges associated with the widespread use of this gene-editing technology require active
engagement with communities and development of clear guidelines to regulate its responsible
and safe use. While using CRISPR-Cas systems that naturally occur on plasmids [35] may
avoid some of the issues associated with the release of genetically engineered organisms,
understanding the consequences associated with large-scale release of any DNA element will
be key for sustainable and risk-free implementation of this technology.
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